Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rumex altissimus pollen extract is a biological allergen extract derived from the pollen of the Pale Dock plant. It is indicated for use in the diagnosis of Pale Dock pollen allergy via skin testing and for the treatment of allergic rhinitis, allergic conjunctivitis, and seasonal asthma through allergen immunotherapy (hyposensitization). The extract contains various proteins that act as allergens; when administered in gradually increasing doses, it induces a state of clinical tolerance. This is achieved by shifting the immune response from a Th2-mediated allergic pathway to a Th1/Treg-mediated pathway, resulting in the production of allergen-specific IgG4 antibodies that block IgE-mediated mast cell and basophil activation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rumex altissimus pollen extract.